Systemic therapy for advanced soft tissue sarcomas: Highlighting novel therapies and treatment approaches

Cancer

Volumn 118, Issue 6, 2012, Pages 1474-1485

  Riedel, Richard F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

maintenance therapy; mammalian target of rapamycin (mTOR) inhibitors; novel therapies; soft tissue sarcoma; tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BRIVANIB; CEDIRANIB; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; GEMCITABINE; IFOSFAMIDE; IMATINIB; INSULIN LIKE GROWTH FACTOR 1 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESNA; NAVELBINE; PACLITAXEL; PALIFOSFAMIDE; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RIDAFOROLIMUS; SORAFENIB; TEMOZOLOMIDE; TH 302; TIVANTINIB; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANEMIA; ANGIOSARCOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GRADING; CANCER SURVIVAL; CARDIOTOXICITY; CLEAR CELL SARCOMA; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; HEMANGIOENDOTHELIOSARCOMA; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; INOPERABLE CANCER; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIPOSARCOMA; LOADING DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MEDICAL DECISION MAKING; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECURRENT CANCER; REVIEW; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE SARCOMA; STOMATITIS; SYNOVIAL SARCOMA; SYSTEMIC THERAPY; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; PROTEIN KINASE INHIBITORS; SARCOMA; TOR SERINE-THREONINE KINASES;

EID: 84858002307     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26415     Document Type: Review

References (109)

1. Clark MA, Fisher C, Judson I, Thomas JM,. Soft-tissue sarcomas in adults. N Engl J Med. 2005; 353: 701-711. (Pubitemid 41175678)
2. Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Soft Tissue Including Heart. Available at:. Accessed August 12, 2010.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
4. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF,. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996; 14: 1679-1689. (Pubitemid 26134227)
5. Kattan MW, Leung DH, Brennan MF,. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002; 20: 791-796. (Pubitemid 34111387)
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. V1. 2011. Available at. Accessed May 11, 2011.
7. Bramwell VH, Anderson D, Charette ML,. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev. 2003; CD003293.
8. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999; 17: 150-157. (Pubitemid 29022388)
9. Benjamin RS, Pisters PW, Helman LJ, Bramwell V, Rubin EH, O'Sullivan B,. Sarcomas of soft tissue. In:, Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna W, eds. Abeloff's Clinical Oncology. 4th ed., Chapter 97. Philadelphia: Churchill Livingston; 2008.
10. Anderson ME, Hornicek FJ, Gebhardt MC, Raskin KA, Mankin HJ,. Alveolar soft part sarcoma: a rare and enigmatic entity. Clin Orthop Relat Res. 2005; 438: 144-148. (Pubitemid 41254329)
11. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY,; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008; 19 (suppl 2): ii89-ii93.
12. Casali PG, Blay JY,. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl 5): v198-v203.
13. Halpern JL, Gilbert J, Holt GE, Schwartz HS,. Chemotherapy for soft tissue sarcoma. Curr Opin Orthop. 2007; 18: 604-610. (Pubitemid 350293726)
14. Longhi A, Ferrari S, Bacci G, Specchia S,. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs. 2007; 18: 737-744. (Pubitemid 47343670)
15. Talbot SM, Keohan ML, Hesdorffer M, et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer. 2003; 98: 1942-1946. (Pubitemid 37310238)
16. Bramwell VH, Anderson D, Charette ML,. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000; 4: 103-112.
17. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987; 5: 840-850. (Pubitemid 17119988)
18. Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987; 23: 1477-1483.
19. van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002; 38: 2397-2406. (Pubitemid 35387492)
20. Buesa JM, Lopez-Pousa A, Martin J, et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol. 1998; 9: 871-876. (Pubitemid 28440446)
21. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007; 25: 3144-3150. (Pubitemid 47218064)
22. Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer. 2005; 104: 1706-1712. (Pubitemid 41437435)
23. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993; 11: 1269-1275. (Pubitemid 23199129)
24. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995; 13: 1537-1545.
25. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11: 1276-1285. (Pubitemid 23199130)
26. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007; 25: 2755-2763. (Pubitemid 47123184)
27. Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007; 109: 1863-1869. (Pubitemid 46668552)
28. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000; 18: 2676-2684. (Pubitemid 30463549)
29. Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol. 1991; 2: 307-309.
30. O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer. 1977; 39: 1940-1948. (Pubitemid 8129025)
31. Lopez M, Vici P, Di Lauro L, Carpano S,. Increasing single epirubicin doses in advanced soft tissue sarcomas. J Clin Oncol. 2002; 20: 1329-1334. (Pubitemid 34177440)
32. Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer. 1998; 78: 1634-1639. (Pubitemid 28550051)
33. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001; 37: 870-877. (Pubitemid 32323965)
34. Skubitz KM,. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest. 2003; 21: 167-176. (Pubitemid 36532162)
35. Chidiac T, Budd GT, Pelley R, et al. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs. 2000; 18: 253-259. (Pubitemid 30599146)
36. Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC] Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol. 1993; 31 (suppl 2): S180-S184.
37. Antman KH, Montella D, Rosenbaum C, Schwen M,. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep. 1985; 69: 499-504. (Pubitemid 15031398)
38. Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995; 13: 1600-1608.
39. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2000; 36: 61-67. (Pubitemid 30035345)
40. Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 1976; 60: 199-203.
41. Duffaud F, Pautier P, Nguyen BB, et al. A pooled analysis of the final results of the 2 randomized phase II studies comparing gemcitabine (G) vs gemcitabine + docetaxel (G + D) in patients (pts) with metastatic/relapsed leiomyosarcoma (LMS) [abstract]. Ann Oncol. 2010; 21 (suppl 8). Abstract 13450.
42. Fayette J, Penel N, Chevreau C, et al. Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs. 2009; 27: 482-489.
43. Binh NN, Chevreau C, Penel N, et al. Consolidation with high-dose chemotherapy for responding patients to standard chemotherapy in advanced, metastatic soft tissue sarcoma (STS): a randomized trial from FNCLCC French Sarcoma Group [abstract]. J Clin Oncol. 2009; 27 (15 suppl). Abstract 10505.
44. Agulnik M, Okuno SH, Von Mehren M, et al. An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma [abstract]. J Clin Oncol. 2009; 27 (15 suppl). Abstract 10533.
45. Casper ES, Waltzman RJ, Schwartz GK, et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest. 1998; 16: 442-446. (Pubitemid 28464852)
46. Skubitz KM, Haddad PA,. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005; 104: 361-366. (Pubitemid 40993264)
47. Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008; 44: 2433-2436.
48. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008; 26: 5269-5274.
49. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27: 3133-3140.
50. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009; 27: 3154-3160.
51. Wollina U, Hansel G, Schonlebe J, et al. Cutaneous angiosarcoma is a rare aggressive malignant vascular tumour of the skin. J Eur Acad Dermatol Venereol. 2011; 25: 964-968.
52. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002; 20: 2824-2831. (Pubitemid 34651511)
53. Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD,. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008; 109: 323-328.
54. Bay JO, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer. 2006; 119: 706-711. (Pubitemid 43955727)
55. Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007; 246: 105-113. (Pubitemid 47012214)
56. Canter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer SA,. Synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008; 14: 8191-8197.
57. Edmonson JH, Ryan LM, Falkson CI, Hicks DG, Blum RH,. Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group. Sarcoma. 2003; 7: 9-11. (Pubitemid 36577841)
58. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010; 46: 72-83.
59. Dileo P, Sanfilippo R, Grosso F, et al. Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): a retrospective analysis of 39 patients (pts) from 3 European institutions [abstract]. J Clin Oncol. 2010; 28 (suppl 15). Abstract 10030.
60. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009; 27: 3126-3132.
61. European Medical Agency. Summary of Product Characteristics (Trabectedin). Available at:. Accessed February 11, 2010.
62. Rinehart KL,. Antitumor compounds from tunicates. Med Res Rev. 2000; 20: 1-27. (Pubitemid 30027559)
63. PharMar SA,. Yondelis in the News, March 10, 2010. Available at:. Accessed March 15, 2011.
64. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005; 23: 576-584. (Pubitemid 46224235)
65. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004; 22: 890-899. (Pubitemid 41103601)
66. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004; 22: 1480-1490. (Pubitemid 41103631)
67. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007; 8: 595-602. (Pubitemid 46995623)
68. Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced L-sarcoma. ClinicalTrials.gov. NCT01343277. Available at:. Accessed June 7, 2011.
69. Cranmer LD, Chawla SP, Rushing DA, et al. Phase I/II study of TH-302 combined with doxorubicin in soft tissue sarcoma. J Clin Oncol. 2010; 28 (suppl 15). Abstract 10036.
70. Verschraegen CF, Chawla SP, Mita MM, et al. A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). J Clin Oncol. 2011; 28 (suppl 15). Abstract 1004.
71. Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-Line Metastatic Soft Tissue Sarcoma (PICASSO III) [abstract]. ClinicalTrials.gov. NCT01168791. Available at:. Accessed June 7, 2011.
72. Van Der Graaf W, Blay J, Chawla SP, et al. PALETTE: a randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-an EORTC STBSG Global Network Study (EORTC 62072) [abstract]. J Clin Oncol. 2011; 29. Abstract LBA10002.
73. Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of sorafenib against desmoid tumor/deep fibromatoses. Clin Cancer Res. 2011; 17: 4082-4090.
74. Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009; 27: 3148-3153.
75. Goldberg J, Demetri GD, Choy E, et al. Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors [abstract]. J Clin Oncol. 2009; 27 (suppl 15). Abstract 10502.
76. Garcia A, Rosen L, Cunningham CC, et al. Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose [abstract]. J Clin Oncol. 2007; 25 (suppl 15). Abstract 3525.
77. Schwartz GK, Maki RG, Ratain MJ, et al. Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): biomarker and subset results of a phase II randomized discontinuation trial [abstract]. J Clin Oncol. 2011; 29. Abstract 10000.
78. Gardner K, Judson I, Leahy M, et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma [abstract]. J Clin Oncol. 2009; 27 (suppl 15). Abstract 10523.
79. Kummar S, Strassberger A, Monks A, et al. An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS) [abstract]. J Clin Oncol. 2011; 29. Abstract 10001.
80. A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas (Axi-STS). ClinicalTrials.gov. NCT01140737. Available at:. Accessed May 12, 2011.
81. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2010; 11: 129-135.
82. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2010; 17: 871-879.
83. Schoffski P, Adkins D, Blay J, et al. Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors [abstract]. J Clin Oncol. 2011; 29. Abstract 10004.
84. Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma. ClinicalTrials.gov. NCT01016015. Available at:. Accessed May 11, 2011.
85. Wan X, Helman LJ,. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007; 12: 1007-1018. (Pubitemid 47359144)
86. MacKenzie AR, von Mehren M,. Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future. Expert Rev Anticancer Ther. 2007; 7: 1145-1154. (Pubitemid 47365007)
87. Merimsky O, Bernstein-Molho R, Sagi-Eisenberg R,. Targeting the mammalian target of rapamycin in myxoid chondrosarcoma. Anticancer Drugs. 2008; 19: 1019-1021.
88. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010; 28: 835-840.
89. Richter S, Pink D, Hohenberger P, et al. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST [abstract]. J Clin Oncol. 2010; 28 (suppl 15). Abstract 10038.
90. Schoffski P, Reichardt P, Blay JY, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010; 21: 1990-1998.
91. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010; 363: 1801-1811.
92. Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the mayo phase 2 consortium (P2C). Cancer 2011; 117: 3468-3475.
93. Hartford CM, Desai AA, Janisch L, et al. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009; 15: 1428-1434.
94. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008; 26: 361-367. (Pubitemid 351171685)
95. Chawla SP, Staddon AP, Baker LH, et al. A phase 2 study of the mTOR inhibitor ridaforolimus (AP23573; MK-8669) in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. In press.
96. Mita MM, Britten CD, Poplin E, et al. Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669) [abstract]. J Clin Oncol. 2008; 26 (Supple 15). Abstract 3509.
97. Bailey HH, Mahoney MR, Ettinger DS, et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer. 2006; 107: 2462-2467. (Pubitemid 44748530)
98. Knowling M, Blackstein M, Tozer R, et al. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs. 2006; 24: 435-439. (Pubitemid 43876080)
99. Birch R, Chawla S, Nemunaitis J, et al. Perifosine (P) as an active agent in the treatment of patients with advanced sarcoma [abstract]. J Clin Oncol. 2007; 25 (suppl 18). Abstract 10059.
100. Schoffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052) [abstract]. J Clin Oncol. 2010; 28 (suppl 15). Abstract 10031.
101. Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma. ClinicalTrials.gov. NCT01327885. Available at:. Accessed May 12, 2011.
102. Baker LH, Rowinsky EK, Mendelson D, et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol. 2008; 26: 5583-5588.
103. Chawla SP, Chua VS, Fernandez L, et al. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy- resistant sarcoma and osteosarcoma. Mol Ther. 2009; 17: 1651-1657.
104. Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas. ClinicalTrials.gov. NCT01106872. Available at:. Accessed May 12, 2011.
105. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010; 11: 521-529.
106. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009; 374: 1432-1440.
107. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003; 21: 2460-2465. (Pubitemid 46606325)
108. Mannel RS, Brady MF, Kohn EC, et al. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2011; 122: 89-94.
109. Chawla SP, Blay J, Ray-Coquard IL, et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT) [abstract]. J Clin Oncol. 2011; 29. Abstract 10005.